Project Grant R01HL176648
Award Date 8/18/25
Completion Date 5/31/29
Dollars Obligated $714K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Vermont, USA
Similar Awards
- This $149,804 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research on the structural and functional features of the native cardiac sarcomere in hypertrophic cardiomyopathy (HCM). The project aims to directly observe the conformational changes in the beta-myosin motor protein caused by HCM-inducing mutations and the FDA-approved drug mavacamten, using advanced cryo-electron tomography...
- The National Heart Lung and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $167,400 project grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Dr. Joshua Meisner at the University of Michigan. The award aims to elucidate the mechanical and metabolic pathways underlying hypertrophic cardiomyopathy caused by truncating variants of the MYBPC3 gene, a leading cause of sudden cardiac death and heart failure, especially in children and adolescents....
- This federal Project Grant award of $730,764 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will fund research at Case Western Reserve University to define the effects of cardiac myosin binding protein C (cMyBP-C) missense variants on cardiac sarcomere molecular structure and function, and link these mechanisms to altered whole organ structure, function, and the development of hypertrophic cardiomyopathy (HCM). The project aims to improve...
- This federal Project Grant award of $777,258 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to advance the understanding of heart failure in hypertrophic cardiomyopathy (HCM) through the use of cardiac magnetic resonance imaging (CMR). The grant will support research by the Beth Israel Deaconess Medical Center, Inc. (BIDMC) to characterize the key pathophysiologic mechanisms of heart failure symptoms in HCM and evaluate the effects of the...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $125,385 to the University of Arizona to investigate the role of mutation-specific activation of the Ca2+/calmodulin-dependent protein kinase II (CaMKII) in the development of hypertrophic cardiomyopathy (HCM). The research aims to elucidate the specific biophysical changes in the cardiac thin filament triggered by different HCM-linked...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $618,045 to the University of Arizona to conduct research on identifying new mechanisms and targets for treating diastolic dysfunction in hypertrophic cardiomyopathy (HCM). The primary objectives are to: 1) fully characterize at the atomic level three specific functional domains of the cardiac thin filament linked to the...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $126,306 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to the University of Washington. The goal of this 2-year award is to establish a system to accelerate the reclassification of variants of unknown significance in the MYH7 gene, which cause hypertrophic cardiomyopathy, and determine the role of genetic modifiers that influence the severity of this disease. The research will utilize human induced pluripotent...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $589,998 to Michigan Technological University to conduct research on cardiac sensory and sympathetic nerve dysregulation in hypertrophic cardiomyopathy (HCM). The 3-year project, starting on September 1, 2025, will investigate how abnormal mechanical and metabolic signals in HCM hearts impact cardiac sensory nerves and contribute to disease progression....
- The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $694,754 project grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The Washington University in Missouri. The 5-year grant, which commenced on August 1, 2025, will support research to investigate the fundamental molecular mechanisms driving the pathogenesis of key troponin cardiomyopathy mutations and their effects on cellular and tissue function. The...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA Program 93.837 - Cardiovascular Diseases Research provides $761,152 to the University of California, San Diego (UCSD) to investigate the gene regulatory mechanisms controlling the expression of cardiac myosin heavy chain (MYH) proteins MYH6 and MYH7. The key products and services delivered under this 4-year project include: Investigating the cis-regulatory sequences that regulate competition between...